Related Experiment Video
Updated: Aug 19, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer
Bao Ming Qin1, Xiao Chen, Jing De Zhu
1Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510663, China.
Abstract:
Lung cancer is one of the leading causes of death with one of the lowest survival rates. However, a subset of lung cancer patients who are of Asian origin and carry somatic mutations in epidermal growth factor receptor or EGFR have responded remarkable well to two tyrosine kinase inhibitors, gefitinib and erlotinib. While EGFR mutation profiles have been reported from Japan, South Korea, and Taiwan, there is no such report from mainland of China where the largest pool of patients reside. In this report, we identified ten somatic mutations from a total of 41 lung cancer patients in China. Among them, seven mutations were found in 17 adenocarcinomas. In contrast to previous reports, eight of these mutations are deletions in exon 19 and two of these deletions are homozygous. These results suggest that a large portion of Chinese adenocarcinoma patients could benefit from gefitinib or erlotinib. This unique mutation profile provides a rationale to develop the next generation of EGFR inhibitors more suitable for the Chinese population.
Insights
Epidermal growth factor receptor (EGFR) mutations in Chinese lung cancer patients show promise for targeted therapies. This study identified specific EGFR mutations in Chinese adenocarcinomas, suggesting potential benefits from gefitinib or erlotinib.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Lung cancer has low survival rates, but certain Asian patients with EGFR mutations respond well to TKIs.
- EGFR mutation data exists for Japan, South Korea, and Taiwan, but not mainland China.
Purpose of the Study:
- To identify somatic mutations in epidermal growth factor receptor (EGFR) in lung cancer patients from mainland China.
- To analyze the EGFR mutation profile in Chinese lung adenocarcinoma patients.
- To assess the potential benefit of tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib.
Main Methods:
- Analysis of ten somatic mutations in 41 lung cancer patients from China.
- Identification of mutations in tumor tissue, specifically focusing on adenocarcinomas.
- Comparison of mutation profiles with previous international reports.
Main Results:
- Ten somatic mutations were identified in 41 Chinese lung cancer patients.
- Seven mutations were found in 17 lung adenocarcinomas.
- A significant finding was eight deletions in exon 19, with two being homozygous, differing from prior reports.
Conclusions:
- A substantial proportion of Chinese lung adenocarcinoma patients may benefit from gefitinib or erlotinib treatment.
- The identified unique EGFR mutation profile in Chinese patients warrants the development of next-generation EGFR inhibitors tailored for this population.
